BR112021026409A2 - Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo - Google Patents

Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo

Info

Publication number
BR112021026409A2
BR112021026409A2 BR112021026409A BR112021026409A BR112021026409A2 BR 112021026409 A2 BR112021026409 A2 BR 112021026409A2 BR 112021026409 A BR112021026409 A BR 112021026409A BR 112021026409 A BR112021026409 A BR 112021026409A BR 112021026409 A2 BR112021026409 A2 BR 112021026409A2
Authority
BR
Brazil
Prior art keywords
lag
antibody
formulation
preparation
formulations
Prior art date
Application number
BR112021026409A
Other languages
English (en)
Inventor
Kaisong Zhou
tianyi Yao
Yidong Ma
Yinjue Wang
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of BR112021026409A2 publication Critical patent/BR112021026409A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo. a presente invenção refere-se às formulações que compreendem um anticorpo anti-lag-3 e, em particular, a formulações farmacêuticas que compreendem um anticorpo que se liga especificamente a moléculas lag-3, um tampão, um estabilizante e um tensoativo. além disso, a presente invenção também se refere ao uso terapêutico ou profilático dessas formulações.
BR112021026409A 2019-06-24 2020-06-24 Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo BR112021026409A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910547168 2019-06-24
PCT/CN2020/098140 WO2020259593A1 (zh) 2019-06-24 2020-06-24 包含抗lag-3抗体的制剂、其制备方法及其用途

Publications (1)

Publication Number Publication Date
BR112021026409A2 true BR112021026409A2 (pt) 2022-03-15

Family

ID=74061513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026409A BR112021026409A2 (pt) 2019-06-24 2020-06-24 Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo

Country Status (9)

Country Link
US (1) US20220251188A1 (pt)
EP (1) EP3991747A4 (pt)
JP (1) JP2022539088A (pt)
KR (1) KR20220036371A (pt)
CN (1) CN114007648B (pt)
AU (1) AU2020304108A1 (pt)
BR (1) BR112021026409A2 (pt)
CA (1) CA3144116A1 (pt)
WO (1) WO2020259593A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
RU2019138507A (ru) * 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
MX2019012076A (es) * 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途

Also Published As

Publication number Publication date
JP2022539088A (ja) 2022-09-07
EP3991747A1 (en) 2022-05-04
CN114007648A (zh) 2022-02-01
US20220251188A1 (en) 2022-08-11
KR20220036371A (ko) 2022-03-22
EP3991747A4 (en) 2023-07-05
EP3991747A9 (en) 2022-10-12
CN114007648B (zh) 2024-02-02
WO2020259593A1 (zh) 2020-12-30
AU2020304108A1 (en) 2022-01-27
CA3144116A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112021026414A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
BR112018002196A2 (pt) formulação anti-ifnar1 estável
EP3916091A3 (en) Dry powder composition comprising long-chain rna
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
BR112018015824A2 (pt) composições para higiene pessoal
EP3928800A3 (en) Dry powder composition comprising long-chain rna
CL2019003032A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
BR112016028942A2 (pt) método para preparar uma composição estável com perfume
BR112019023846A2 (pt) composição farmacêutica de anticorpo de pd-l1 e uso da mesma
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112017009545B8 (pt) Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária
CL2022002963A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112018073690A2 (pt) formulação contendo agonista de tlr e métodos de uso
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112018073862A2 (pt) composição para cuidado dos cabelos
BR112021019612A2 (pt) Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
BR112021026409A2 (pt) Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo
BR112022022919A2 (pt) Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".
BR112019023074A2 (pt) composição contendo ciclodextrina e bussulfano